CRISPR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. 

CEO
Samarth Kulkarni
CEOSamarth Kulkarni
Employees
—
Employees—
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2013
Founded2013
Employees
—
Employees—

CRSP Key Statistics

Market cap
3.89B
Market cap3.89B
Price-Earnings ratio
-8.46
Price-Earnings ratio-8.46
Dividend yield
—
Dividend yield—
Average volume
2.34M
Average volume2.34M
High today
$41.00
High today$41.00
Low today
$40.30
Low today$40.30
Open price
$40.19
Open price$40.19
Volume
10.91K
Volume10.91K
52 Week high
$63.45
52 Week high$63.45
52 Week low
$39.80
52 Week low$39.80

Stock Snapshot

The current CRISPR(CRSP) stock price is $41.00, with a market capitalization of 3.89B. The stock trades at a price-to-earnings (P/E) ratio of -8.46.

During the trading session on 2026-11-18, CRISPR(CRSP) shares reached a daily high of $41.00 and a low of $40.30. At a current price of $41.00, the stock is +1.7% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 10.91K, compared to an average daily volume of 2.34M.

The stock's 52-week range extends from a low of $39.80 to a high of $63.45.

The stock's 52-week range extends from a low of $39.80 to a high of $63.45.

CRSP News

Simply Wall St 3h
CRISPR Therapeutics Could Be 46% Undervalued After Fresh CTX310 Data - Simply Wall St

...

CRISPR Therapeutics Could Be 46% Undervalued After Fresh CTX310 Data - Simply Wall St
Zacks 1d
CRISPR Therapeutics AG is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP Quick QuoteCRSP - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want t...

CRISPR Therapeutics AG is Attracting Investor Attention: Here is What You Should Know
TipRanks 5d
CRISPR Therapeutics Advances CTX460 Gene-Editing Study for Severe Lung Disease

Crispr Therapeutics (CRSP) announced an update on their ongoing clinical study. Study Overview: Crispr Therapeutics is testing CTX460 in adults with emphysema...

Analyst ratings

57%

of 23 ratings
Buy
56.5%
Hold
43.5%
Sell
0%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.